*Please note that this translation is to be used solely as reference.

In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.

First Half of FY 2023

Financial Results Briefing

Friday, November 25, 2022

Linical Co.,Ltd.

TSE Prime 2183

Contents

1. Company Overview

P. 2 - 4

2. Financial Results for the Six Months

Ended September 30, 2022

P. 5 - 13

3. Growth Strategy

P. 14 - 39

1． Company Overview

Global CRO from Japan

  • Locations of Overseas Bases

Sweden

Portugal

Germany

Spain Czech Republic

Poland France

Hungary Romania

UK Netherlands

Italy

October 2022

Establishment of an

Italian subsidiary

Beijing

Canada

Korea

Tokyo

San Diego

New York

Shanghai

Osaka

India

(Linical Headquarters)

Florida

Taiwan

Mexico

Philippines

Singapore

Brazil

Indonesia

Australia

Chile

Argentina

Red: Headquarters Orange: Branch Pink: Subsidiary Blue: Subsidiary Green: CRA Employment ash: Under consideration as base

Linical aims to be a global CRO originating in Japan and undertakes to new drug development as a drug development professional

We have advanced overseas positively since the founding of the company and currently operate in 18 countries and regions

3

The Three Businesses of Linical

  • We specialize in clinical development and cover the entire process from the innovative drug development stage through to the new drug development and approval stages.

Innovative drug

development

process

Basic research

Application to

Clinical trials

Post-marketing

(2 to 3 years) to

New drug

surveillance and

start a new

phases I to III

non-clinical trials

application

clinical trials

drug trial

(3 to 7 years)

(3 to 5 years)

(4 to 10 years)

The three

businesses of

Linical

CRO business

Contract Medical Affairs

From 2005

From 2011

Innovative Drug

● Market analysis ● Handling of pharmaceutical affairs

Development Business● Development strategy planning ● Partnering support

From 2016

  • We have developed three businesses centered on CRO business.

• Contract Medical Affairs business:

We support post-marketing clinical research and marketing activities

  • Innovative Drug Development Business :We provide consulting services that give total support for a wide range of pharmaceutical development activities including market analysis, the formulation of pharmaceutical affairs and development strategies, the selection of marketing partners, and the conclusion of contracts.

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Linical Co. Ltd. published this content on 27 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 December 2022 11:19:48 UTC.